We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Somaxon Pharmaceuticals, Inc. (MM) | NASDAQ:SOMX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
Somaxon Pharmaceuticals Inc. (SOMX) disclosed it filed a patent-infringement lawsuit against Par Pharmaceutical Inc. (PRX), following Par's request for approval to market generic versions of sleep aid Silenor in the U.S.
The suit is Somaxon's latest against a generic applicant for Silenor, its first product on the market. In February, it filed a separate lawsuit against Par that involved a different patent also related to Silenor. It has also engaged in litigation with companies such as Mylan Inc. (MYL).
Par couldn't immediately be reached for comment.
Somaxon reported earlier this month its first-quarter loss widened sharply on higher costs, though it reported product sales, of which it had none a year earlier.
Somaxon's shares closed down Friday at $2.35, while Par finished higher at $33.62. Neither was active after-hours.
-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; matthew.jarzemsky@dowjones.com
1 Year Somaxon Chart |
1 Month Somaxon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
